이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

지역사회 획득 폐렴에 대한 무작위, 임베디드, 다단계 적응형 플랫폼 시험 (REMAP-CAP)

2026년 10월 30일 업데이트: Lennie Derde, UMC Utrecht

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised patients admitted to intensive care with respiratory tract infections.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Background: Respiratory tract infections that are of sufficient severity to require admission to hospital are associated with substantial mortality. All hospitalized patients with respiratory tract infections will receive therapy that consists of a combination of multiple different treatments. For many of these treatments, different options are available currently. For example, several antibiotics exist that are active against the microorganisms that commonly cause pneumonia but it is not known if one antibiotic strategy is best, or whether all suitable antibiotic strategies have similar levels of effectiveness. Of all the treatments that clinicians use for patients with respiratory tract infections, only a small minority have been tested in randomized controlled trials to determine their comparative effectiveness. As a consequence, the standard treatments that are administered vary between and within countries. Current conventional clinical trials methods to assess the efficacy of treatments for respiratory tract infections generally compare two treatment options (either two options for the same treatment modality, where both are in common use; or a new treatment against no treatment or placebo, where the effectiveness of the new treatment is not known). Using this approach, in a series of separate and sequential trials, it will take an inordinate length of time to study all the treatment options. Additionally, with conventional trial designs it is not possible to evaluate interactions between treatment options.

Aim: The primary objective of this platform trial is, for patients hospitalized with respiratory tract infection, to identify the effect of a range of interventions to improve patient outcomes.

Methods: The study will enroll hospitalized patients with respiratory tract infection using a trial design known as a REMAP, which is a type of platform trial. Within this platform trial, eligible participants will be randomized to receive one intervention in each of one or more domains. The primary outcome is a composite of 90-day all-cause mortality and, among survivors, a daily ordinal scale analyzed as a trajectory of illness and recovery to 28-days. There will also be both Platform and domain-specific secondary outcome measures.

In a conventional trial enrollment continues until a pre-specified sample size is obtained, at which time enrollment ceases and the trial data are analyzed to obtain a result. The possible results are that a difference is detected, or no that no difference is detected. However, when the conclusion of the statistical test is "no difference", this could reflect that there truly is no meaningful difference or that the result is indeterminate (i.e., it is possible that if more patients had been enrolled a clinically relevant difference may have been detected).

In comparison to a conventional trial this Platform uses an adaptive design that:

avoids indeterminate results by concluding an answer to a question when sufficient data have accrued (not when a pre-specified sample is reached);
utilizes already accrued data to increase the likelihood that patients within the trial are more likely to be randomized to treatments that are more likely to be beneficial;
is intended to be perpetual (or at least open-ended), substituting new questions in series as initial questions are answered; and
can evaluate the interaction between interventions in different domains, added at different timepoints into the Platform.

Bayesian statistical methods will be used to define Statistical Triggers that reflect thresholds for decision making within a domain. While a limited number of initial treatments and treatment domains were specified at initiation, other interventions and domains have been evaluated over time, and it is planned that this platform trial will continue to evaluate other treatments in the future. Furthermore, in the event of a future epidemic, this Platform is able to adapt to evaluate the most relevant treatment options.

연구 유형

중재적

등록 (추정된)

20000

단계

3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

이름: Cameron Green, MSc
이메일: info@remapcap.org

연구 연락처 백업

이름: Svenja Peters, MSc
이메일: EU.remapcap@umcutrecht.nl

연구 장소

네덜란드
- - 's-Hertogenbosch, 네덜란드
    - 모병
    - Jeroen Bosch Ziekenhuis
    - 연락하다:
      
      Koen Simons, M.D.
  - Almelo, 네덜란드, 7609PP
    - 모병
    - ZGT Almelo
    - 연락하다:
      
      Bastiaan Wittekamp, MD
  - Amersfoort, 네덜란드
    - 모병
    - Meander Medisch Centrum
    - 연락하다:
      
      Laura van Gulik, M.D.
  - Amsterdam, 네덜란드, 1091AC
    - 모집하지 않고 적극적으로
    - OLVG
  - Arnhem, 네덜란드, 6815AD
    - 모병
    - Rijnstate Hospital
    - 연락하다:
      
      Robert-Jan Hassing, MD
  - Deventer, 네덜란드, 7416SE
    - 모집하지 않고 적극적으로
    - Deventer Hospital
  - Ede, 네덜란드, 6716RP
    - 모집하지 않고 적극적으로
    - Ziekenhuis Gelderse Vallei
  - Eindhoven, 네덜란드, 5631BM
    - 모집하지 않고 적극적으로
    - Maxima Medisch Centrum Eindhoven
  - Groningen, 네덜란드
    - 빼는
    - Martini Hospital Groningen
  - Groningen, 네덜란드
    - 모집하지 않고 적극적으로
    - University Medical Center Groningen
  - Leeuwarden, 네덜란드, 8934AD
    - 모집하지 않고 적극적으로
    - Medisch Centrum Leeuwarden
  - Leiden, 네덜란드
    - 모병
    - Leiden University Medical Center
    - 연락하다:
      
      Evert De Jonge, Prof.
  - Nijmegen, 네덜란드
    - 모병
    - Radboud University Medical Center
    - 연락하다:
      
      Frank van de Veerdonk, Prof.
  - Nijmegen, 네덜란드
    - 모병
    - Canisius Wilhelmina Ziekenhuis
    - 연락하다:
      
      Oscar Hoiting, M.D.
  - Roermond, 네덜란드, 6043CV
    - 모집하지 않고 적극적으로
    - Laurentius Hospital
  - Rotterdam, 네덜란드, 3079DZ
    - 모병
    - Maasstad Ziekenhuis
    - 연락하다:
      
      Corstiaan den Uil, MD
  - The Hague, 네덜란드, 2545AA
    - 모병
    - Hagaziekenhuis
    - 연락하다:
      
      Thomas Ottens, MD
  - Uden, 네덜란드, 5406PT
    - 모집하지 않고 적극적으로
    - Bernhoven Hospital
- Utrecht
  - Utrecht, Utrecht, 네덜란드, 3584 CX
    - 모병
    - University Medical Center Utrecht
    - 연락하다:
      
      Marc Bonten, Prof.
    - 연락하다:
      
      Lennie Derde, MD
네팔
- - Bharatpur, 네팔, 44200
    - 모병
    - Chitwan Medical College
    - 연락하다:
      
      Basanta Gauli, MD
  - Kathmandu, 네팔, 44600
    - 모병
    - Grande International Hospital
    - 연락하다:
      
      Sushil Khanal, MD
  - Kathmandu, 네팔, 44600
    - 모병
    - Hospital for Advanced Medicine and Surgery (HAMS)
    - 연락하다:
      
      Hem Paneru, MD
  - Kathmandu, 네팔, 44600
    - 모병
    - Nepal Mediciti
    - 연락하다:
      
      Diptesh Aryal, MD
뉴질랜드
- - Auckland, 뉴질랜드, 0620
    - 모병
    - North Shore Hospital
    - 연락하다:
      
      Robert Everitt, MD
  - Auckland, 뉴질랜드, 1023
    - 모병
    - CVICU, Auckland City Hospital
    - 연락하다:
      
      Shay McGuinness, MD
  - Auckland, 뉴질랜드, 1023
    - 모병
    - DCCM, Auckland City Hospital
    - 연락하다:
      
      Colin McArthur, MD
  - Auckland, 뉴질랜드, 2104
    - 모병
    - Middlemore Hospital
    - 연락하다:
      
      Tony Williams, MD
  - Christchurch, 뉴질랜드, 8011
    - 모병
    - Christchurch Hospital
    - 연락하다:
      
      Jay Ritzema-Carter, MD
  - Hamilton, 뉴질랜드, 3204
    - 모병
    - Waikato Hospital
    - 연락하다:
      
      Robert Martynoga, MD
  - New Plymouth, 뉴질랜드, 4310
    - 모병
    - Taranaki Base Hospital
    - 연락하다:
      
      Jonathan Albrett, MD
  - Rotorua, 뉴질랜드, 3010
    - 모병
    - Rotorua Hospital
    - 연락하다:
      
      Ulrike Buehner, MD
  - Tauranga, 뉴질랜드, 3112
    - 모병
    - Tauranga Hospital
    - 연락하다:
      
      Troy Browne, MD
  - Wellington, 뉴질랜드, 6021
    - 모병
    - Wellington Regional Hospital
    - 연락하다:
      
      Paul Young, MD
  - Whangarei, 뉴질랜드, 0148
    - 모병
    - Whangarei Hospital
    - 연락하다:
      
      Ralph Fuchs, MD
독일
- - Berlin, 독일, 10117
    - 빼는
    - Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie
  - Berlin, 독일, 12351
    - 완전한
    - Vivantes Klinikum Neukölln
  - Berlin, 독일, 13509
    - 빼는
    - Vivantes Humboldt-Klinikum
  - Berlin, 독일, 13353
    - 정지된
    - Charite Universitätsmedizin Berlin
  - Cologne, 독일, 50937
    - 빼는
    - University Hospital of Cologne
  - Cottbus, 독일, 03058
    - 완전한
    - Carl-Thiem-Klinikum Cottbus
  - Dortmund, 독일, 44137
    - 완전한
    - Klinikum Dortmund
  - Essen, 독일, 45138
    - 완전한
    - Elisabeth Hospital Essen
  - Frankfurt, 독일, 60590
    - 빼는
    - Universitätsklinikum Frankfurt
  - Hamburg, 독일, 20251
    - 정지된
    - University Medical Center Hamburg-Eppendorf (UKE)
  - Jena, 독일, 07747
    - 정지된
    - Universitätsklinikum Jena
  - Leipzig, 독일, 04103
    - 정지된
    - University Hospital Leipzig
  - Leipzig, 독일, 04103
    - 정지된
    - Universitätsklinikum Leipzig
  - München, 독일, 81675
    - 정지된
    - Klinikum rechts der Isar der TU München
  - Münster, 독일, 48149
    - 정지된
    - Universitätsklinikum Münster
  - Tübingen, 독일, 72076
    - 완전한
    - Universitäts Klinikum Tübingen
  - Würzburg, 독일, 97080
    - 정지된
    - Universitätsklinikum Würzburg
루마니아
- - Bucharest, 루마니아, 030303
    - 정지된
    - Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes"
미국
- Florida
  - Jacksonville, Florida, 미국, 32209
    - 모병
    - University of Florida
    - 연락하다:
      
      Hadi Hatoum, MD
- Georgia
  - Augusta, Georgia, 미국, 30912
    - 아직 모집하지 않음
    - Augusta University
    - 연락하다:
      
      Jose Vazquez, MD
- Illinois
  - Chicago, Illinois, 미국, 60612
    - 모병
    - University of Illinois Health
    - 연락하다:
      
      Jeffrey Jacobson, MD
- Louisiana
  - New Orleans, Louisiana, 미국, 70112
    - 아직 모집하지 않음
    - Tulane Medical Center
    - 연락하다:
      
      Joshua Denson, MD
- Michigan
  - Ann Arbor, Michigan, 미국, 48109
    - 모병
    - University of Michigan
    - 연락하다:
      
      Robert Hyzy, MD
- New York
  - New York, New York, 미국, 10065
    - 모병
    - Memorial Sloan Kettering Cancer Center
    - 연락하다:
      
      Stephen Pastores, MD
- North Carolina
  - Winston-Salem, North Carolina, 미국, 27157-1009
    - 아직 모집하지 않음
    - Wake Forest Baptist Health
    - 연락하다:
      
      Ashish Khanna, MD
- Ohio
  - Columbus, Ohio, 미국, 43210
    - 모병
    - The Ohio State University Wexner Medical Center
    - 연락하다:
      
      Matthew Exline, MD
- Oregon
  - Portland, Oregon, 미국, 97239-3098
    - 모병
    - Oregon Health and Science University
    - 연락하다:
      
      Akram Khankhana, MD
- Pennsylvania
  - Pittsburgh, Pennsylvania, 미국
    - 모병
    - University of Pittsburgh Medical Centre
    - 연락하다:
      
      Stephanie Mongomery
- Rhode Island
  - Providence, Rhode Island, 미국, 02903
    - 아직 모집하지 않음
    - Brown University - Rhode Island Hospital
    - 연락하다:
      
      Mitchell Levy, MD
벨기에
- - Charleroi, 벨기에, 6042
    - 모병
    - CHU de Charleroi - Hôpital Civil Marie Curie
    - 연락하다:
      
      Patrick Biston, MD
  - Ghent, 벨기에, 9000
    - 모병
    - Universitair Ziekenhuis Gent
    - 연락하다:
      
      Pieter Depuydt, Prof.
  - Namur, 벨기에, 5530
    - 모병
    - CHU Namur site Godinne
    - 연락하다:
      
      Pierre Bulpa, MD
사우디 아라비아
- - Riyadh, 사우디 아라비아, 14611
    - 모병
    - King Abdulaziz Medical City
    - 연락하다:
      
      Yaseen Arabi, MD
세르비아
- - Belgrade, 세르비아, 11000
    - 정지된
    - University Hospital Center Dr Dragiša Mišović
  - Belgrade, 세르비아, 11000
    - 정지된
    - University Clinical Centre of Serbia
  - Niš, 세르비아, 18000
    - 모병
    - Clinical Centre of Niš
    - 연락하다:
      
      Tanja Pejčić, MD
스위스
- - Zurich, 스위스, 8091
    - 정지된
    - University Hospital Zürich
스페인
- - Barcelona, 스페인
    - 모병
    - Hospital del Mar
    - 연락하다:
      
      Rosana Munoz-Bermúdez, M.D.
  - Cadiz, 스페인, 11407
    - 모병
    - Hospital Universitario de Jerez
    - 연락하다:
      
      Ángel Estella, MD
  - Córdoba, 스페인, 14004
    - 모병
    - Reina Sofia University Hospital
    - 연락하다:
      
      Eduardo Aguilar Alonso, M.D.
  - Madrid, 스페인, 28034
    - 모병
    - Ramon y Cajal University Hospital
    - 연락하다:
      
      Cruz Soriano, MD
  - Málaga, 스페인, 29010
    - 모병
    - Hospital Regional de Málaga
    - 연락하다:
      
      Manuel Herrera Gutiérrez, MD
  - Ourense, 스페인, 32005
    - 모병
    - Hospital Universitario de Ourense
    - 연락하다:
      
      Pablo Vidal, MD
  - Santander, 스페인, 39008
    - 모병
    - Hospital Marqués de Valdecilla
    - 연락하다:
      
      Borja Suberviola, MD
  - Tortosa, 스페인, 43500
    - 모병
    - Hospital Verge de la Cinta
    - 연락하다:
      
      Ferran Roche Campo, MD
  - Valencia, 스페인, 46026
    - 모병
    - Hospital La Fe
    - 연락하다:
      
      Paula Ramírez, MD
  - Valencia, 스페인, 46017
    - 모병
    - Doctor Peset University Hospital
    - 연락하다:
      
      Rafael Zaragoza, MD
슬로베니아
- - Golnik, 슬로베니아, 4204
    - 정지된
    - University Clinic of Respiratory and Allergic Diseases Golnik
  - Maribor, 슬로베니아, 2000
    - 모병
    - University Medical Centre Maribor
    - 연락하다:
      
      Andre Markota, MD
아일랜드
- - Cork, 아일랜드, T12 DC4A
    - 모집하지 않고 적극적으로
    - Cork University Hospital
  - Dublin, 아일랜드
    - 모병
    - Beaumont Hospital
    - 연락하다:
      
      Ger Curley, Prof.
  - Dublin, 아일랜드
    - 모병
    - St. Vincent's University Hospital
    - 연락하다:
      
      Alistair Nichol, Prof.
  - Galway, 아일랜드
    - 모병
    - University Hospital Galway
    - 연락하다:
      
      John Laffey, M.D.
  - Waterford, 아일랜드, X91 ER8E
    - 모집하지 않고 적극적으로
    - University Hospital Waterford
에스토니아
- - Tartu, 에스토니아, 50406
    - 정지된
    - Tartu University Hospital
영국
- - Belfast, 영국, BT16 1RH
    - 모병
    - Ulster Hospital
    - 연락하다:
      
      Christopher Murray, MD
  - Bristol, 영국, BS2 8BJ
    - 모병
    - Bristol Royal Childrens Hospital
    - 연락하다:
      
      Jolanta Bernatoniene, MD
  - Bury, 영국, BL9 7TD
    - 모병
    - Fairfield General Hospital
    - 연락하다:
      
      Andrew Claxton, MD
  - Crewe, 영국, CW1 4QJ
    - 모병
    - Leighton Hospital
    - 연락하다:
      
      Richard Lowsby, MD
  - Dorchester, 영국, DT1 2JY
    - 완전한
    - Dorset County Hospital
  - Gloucester, 영국, GL1 3NN
    - 완전한
    - Gloucester Royal Hospital
  - Haywards Heath, 영국, RH16 4EX
    - 모집하지 않고 적극적으로
    - The Princess Royal Hospital Haywards Heath
  - Leeds, 영국, LS9 7TF
    - 모병
    - St. James University Hospital
    - 연락하다:
      
      E Paramasivam, MD
  - London, 영국, NW1 2BU
    - 모병
    - University College London Hospital
    - 연락하다:
      
      Michael Marks, MD
  - London, 영국, SW10 9NH
    - 모병
    - Chelsea and Westminster Hospital
    - 연락하다:
      
      Roger Davies, MD
  - London, 영국, E9 6SR
    - 정지된
    - Homerton Hospital
  - Margate, 영국, CT9 4AN
    - 정지된
    - Queen Elizabeth and Queen Mother Hospital
  - Newcastle upon Tyne, 영국, NE1 4LP
    - 모병
    - Newcastle Royal Victoria Infirmary (Paediatrics)
    - 연락하다:
      
      Marieke Emonts, MD
  - North Shields, 영국, Ne29 8NH
    - 정지된
    - North Tyneside General Hospital
  - Warwick, 영국, CV34 5BW
    - 모집하지 않고 적극적으로
    - Warwick Hospital
  - West Bromwich, 영국, B71 4HJ
    - 모병
    - Sandwell General Hospital
    - 연락하다:
      
      Jonathan Hulme, MD
- England
  - Basildon, England, 영국, SS16 5NL
    - 모집하지 않고 적극적으로
    - Basildon Hospital
  - Basingstoke, England, 영국, RG24 9NA
    - 모병
    - Basingstoke and North Hampshire Hospital
    - 연락하다:
      
      Irena Grecu, MD
  - Bath, England, 영국, BA1 3NG
    - 모집하지 않고 적극적으로
    - Royal United Hospital, Bath
  - Birmingham, England, 영국, B15 2TH
    - 모병
    - Queen Elizabeth Hospital Birmingham
    - 연락하다:
      
      Dhruv Parekh
  - Birmingham, England, 영국, B18 7QH
    - 모병
    - Birmingham City Hospital
    - 연락하다:
      
      Jonathan Hulme
  - Blackburn, England, 영국, BB2 3HH
    - 모병
    - Royal Blackburn Teaching Hospital
    - 연락하다:
      
      Srikanth Chukkambotla, MD
  - Boston, England, 영국, PE21 9QS
    - 정지된
    - Pilgrim Hospital ULHT
  - Bournemouth, England, 영국, BH7 7DW
    - 모집하지 않고 적극적으로
    - Royal Bournemouth Hospital
  - Brighton, England, 영국, BN2 5BE
    - 정지된
    - Royal Sussex County Hospital
  - Bristol, England, 영국, BS10 5NB
    - 정지된
    - Southmead Hospital
  - Bristol, England, 영국, BS2 8EX
    - 모집하지 않고 적극적으로
    - Bristol Royal Infirmary
  - Burton-on-Trent, England, 영국, DE13 0RB
    - 모집하지 않고 적극적으로
    - Queen's Hospital, Burton
  - Cambridge, England, 영국, CB2 0AY
    - 모집하지 않고 적극적으로
    - Royal Papworth Hospital
  - Cambridge, England, 영국, CB2 0QQ
    - 모집하지 않고 적극적으로
    - Addenbrookes Hospital
  - Carlisle, England, 영국, CA2 7HY
    - 정지된
    - North Cumberland Infirmary
  - Chertsey, England, 영국, KT16 0P
    - 모집하지 않고 적극적으로
    - St Peter's Hospital
  - Chester, England, 영국, CH2 1UL
    - 모집하지 않고 적극적으로
    - Countess of Chester Hospital
  - Chesterfield, England, 영국, S44 5BL
    - 모병
    - Chesterfield Royal Hospital
    - 연락하다:
      
      Euan Mackay
  - Colchester, England, 영국, CO4 5JL
    - 모병
    - Colchester Hospital
    - 연락하다:
      
      Mohamed Ramali
  - Coventry, England, 영국, CV2 2DX
    - 모집하지 않고 적극적으로
    - University Hospital Coventry
  - Darlington, England, 영국, DL3 6HX
    - 정지된
    - Darlington Memorial Hospital
  - Dartford, England, 영국, DA2 8DA
    - 빼는
    - Darent Valley Hospital
  - Dudley, England, 영국, DY1 2HQ
    - 모집하지 않고 적극적으로
    - Russells Hall Hospital
  - Exeter, England, 영국, Ex2 5DW
    - 정지된
    - Royal Devon and Exeter Hospital
  - Frimley, England, 영국, GU16 7 UJ
    - 정지된
    - Frimley Park Hospital
  - Gateshead, England, 영국, NE9 6SX
    - 모집하지 않고 적극적으로
    - Queen Elizabeth Hospital Gateshead
  - Gillingham, England, 영국, ME7 5NY
    - 완전한
    - Medway Maritime Hospital
  - Great Yarmouth, England, 영국, NR31 6LA
    - 완전한
    - James Paget University Hospital
  - Guildford, England, 영국, GU2 7XX
    - 모병
    - Royal Surrey County Hospital
    - 연락하다:
      
      Ben Creagh-Brown
  - Harrow, England, 영국, HA1 3UJ
    - 모집하지 않고 적극적으로
    - Northwick Park Hospital
  - Hereford, England, 영국, HR1 2ER
    - 모병
    - Hereford County Hospital
    - 연락하다:
      
      Charlotte Small
  - High Barnet, England, 영국, EN5 3DJ
    - 모집하지 않고 적극적으로
    - Barnet Hospital
  - Huddersfield, England, 영국, HD3 3EA
    - 모집하지 않고 적극적으로
    - Huddersfield Royal Infirmary
  - Ilford, England, 영국, IG3 8YB
    - 모집하지 않고 적극적으로
    - King George Hospital
  - Ipswich, England, 영국, IP4 5PD
    - 빼는
    - Ipswich Hospital
  - Kettering, England, 영국, NN16 8UZ
    - 모병
    - Kettering Hospital
    - 연락하다:
      
      Dhinesh Sundaran
  - Leeds, England, 영국, LS9 7TF
    - 모집하지 않고 적극적으로
    - Leeds General Infirmary
  - Leicester, England, 영국, LE1 5WW
    - 정지된
    - Leicester Royal Infirmary
  - Leicester, England, 영국, LE3 9QP
    - 정지된
    - Glenfield Hospital
  - Lincoln, England, 영국, LN2 5QY
    - 정지된
    - Lincoln County Hospital
  - Liverpool, England, 영국, L7 8XP
    - 모집하지 않고 적극적으로
    - Royal Liverpool University Hospital
  - Liverpool, England, 영국, L14 3PE
    - 완전한
    - Liverpool Heart and Chest Hospital
  - Liverpool, England, 영국, L14 5AB
    - 완전한
    - Alder Hey Hospital
  - Liverpool, England, 영국, L9 7AL
    - 정지된
    - University Hospital Aintree
  - London, England, 영국, SE5 9RS
    - 모병
    - King's College Hospital
    - 연락하다:
      
      Phillip Hopkins
  - London, England, 영국, W12 0HS
    - 모병
    - Hammersmith Hospital
    - 연락하다:
      
      Stephen Brett
  - London, England, 영국, W2 1NY
    - 모병
    - St Mary's Hospital
    - 연락하다:
      
      Anthony Gordon
  - London, England, 영국, W6 8RF
    - 모병
    - Charing Cross Hospital
    - 연락하다:
      
      David Antcliffe
  - London, England, 영국, CR7 7YE
    - 모집하지 않고 적극적으로
    - Croydon University Hospital
  - London, England, 영국, E1 1FR
    - 모집하지 않고 적극적으로
    - Royal London Hospital
  - London, England, 영국, E11 1NR
    - 모집하지 않고 적극적으로
    - Whipps Cross Hospital
  - London, England, 영국, E13 8SL
    - 모집하지 않고 적극적으로
    - Newham University Hospital
  - London, England, 영국, EC1A 7BE
    - 모집하지 않고 적극적으로
    - St Bartholomew's Hospital
  - London, England, 영국, N18 1QX
    - 모집하지 않고 적극적으로
    - North Middlesex University Hospital
  - London, England, 영국, NW3 2QG
    - 모집하지 않고 적극적으로
    - Royal Free Hospital
  - London, England, 영국, SE1 7EH
    - 모병
    - St Thomas Hospital
    - 연락하다:
      
      Marlies Ostermann
  - London, England, 영국, SE1 9RT
    - 모집하지 않고 적극적으로
    - Guy's Hospital
  - London, England, 영국, SE18 4QH
    - 모집하지 않고 적극적으로
    - Queen Elizabeth Hospital, Woolwich
  - London, England, 영국, SW3 6JJ
    - 모집하지 않고 적극적으로
    - Royal Marsden Hospital
  - London, England, 영국, SW3 6NP
    - 모집하지 않고 적극적으로
    - Royal Brompton Hospital
  - London, England, 영국, SW17 0QT
    - 모병
    - St George's University Hospital
    - 연락하다:
      
      Susannah Leaver
  - Luton, England, 영국, LU4 0DZ
    - 정지된
    - Luton and Dunstable University Hospital
  - Maidstone, England, 영국, ME16 9QQ
    - 모병
    - Maidstone Hospital
    - 연락하다:
      
      David Golden, MD
  - Manchester, England, 영국, M13 9WL
    - 정지된
    - Manchester Royal Infirmary
  - Manchester, England, 영국, M20 4BX
    - 완전한
    - The Christie Hospital
  - Manchester, England, 영국, M23 9LT
    - 정지된
    - Wythenshawe Hospital
  - Manchester, England, 영국, M8 5RB
    - 모집하지 않고 적극적으로
    - North Manchester General Hospital
  - Metropolitan Borough of Wirral, England, 영국, CH49 5PE
    - 모병
    - Arrowe Park Hospital
    - 연락하다:
      
      Craig Denmade, MD
  - Middlesbrough, England, 영국, TS4 3BW
    - 모병
    - The James Cook University Hospital
    - 연락하다:
      
      Jeremy Henning, MD
  - Milton Keynes, England, 영국, MK6 5LD
    - 모병
    - Milton Keynes University Hospital
    - 연락하다:
      
      Richard Stewart, MD
  - Newcastle, England, 영국, NE1 4LP
    - 정지된
    - Royal Victoria Infirmary, Newcastle
  - Newcastle, England, 영국, NE7 7DN
    - 정지된
    - Newcastle Freeman Hospital
  - Northampton, England, 영국, NN1 5BD
    - 정지된
    - Northampton General Hospital
  - Norwich, England, 영국, NR4 7UY
    - 완전한
    - Norfolk and Norwich University Hospital
  - Nottingham, England, 영국, NG5 1PB
    - 모병
    - City Hospital Nottingham
    - 연락하다:
      
      Daniel Harvey, MD
  - Nottingham, England, 영국, NG7 2UH
    - 모병
    - Queen's Medical Centre - Nottingham University Hospitals NHS Trust
    - 연락하다:
      
      Daniel Harvey, MD
  - Nuneaton, England, 영국, CV10 7DJ
    - 모집하지 않고 적극적으로
    - George Eliot Hospital
  - Oldham, England, 영국, Ol1 2JH
    - 모병
    - Royal Oldham Hospital
    - 연락하다:
      
      Redmond Tully, MD
  - Orpington, England, 영국, BR6 8ND
    - 정지된
    - Princess Royal University Hospital
  - Oxford, England, 영국, OX3 9DU
    - 모집하지 않고 적극적으로
    - John Radcliffe Hospital
  - Plymouth, England, 영국, PL6 8DH
    - 모병
    - Derriford Hospital
    - 연락하다:
      
      Nikitas Nikitas, MD
  - Poole, England, 영국, BH15 2JB
    - 모병
    - Poole Hospital NHS Foundation Trust
    - 연락하다:
      
      Henrik Reschreiter, MD
  - Portsmouth, England, 영국, PO6 3LY
    - 모병
    - Queen Alexandra Hospital
    - 연락하다:
      
      David Pogson, MD
  - Prescot, England, 영국, L35 5DR
    - 종료됨
    - Whiston Hospital
  - Preston, England, 영국, PR2 9HT
    - 정지된
    - Royal Preston Hospital
  - Reading, England, 영국, RG1 5AN
    - 모병
    - Royal Berkshire Hospital
    - 연락하다:
      
      Andrew Walden, MD
  - Redditch, England, 영국, B98 7UB
    - 모집하지 않고 적극적으로
    - Alexandra Hospital, Redditch
  - Romford, England, 영국, RM7 0AG
    - 모집하지 않고 적극적으로
    - Queen's Hospital Romford
  - Rotherham, England, 영국, S60 2UD
    - 모병
    - Rotherham Hospital
    - 연락하다:
      
      Anil Hormis, MD
  - Royal Tunbridge Wells, England, 영국, TN2 4QJ
    - 모병
    - Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust
    - 연락하다:
      
      David Golden, MD
  - Salford, England, 영국, M6 8HD
    - 모병
    - Salford Royal Hospital
    - 연락하다:
      
      Paul Dark, MD
  - Salisbury, England, 영국, SP2 8BJ
    - 모병
    - Salisbury District Hospital
    - 연락하다:
      
      Phil Donnison, MD
  - Sheffield, England, 영국, S10 2JF
    - 모병
    - Royal Hallamshire Hospital
    - 연락하다:
      
      Gary Mills, MD
  - Sheffield, England, 영국, S5 7AU
    - 모병
    - Northern General Hospital
    - 연락하다:
      
      Gary Mills, MD
  - Slough, England, 영국, SL2 4HL
    - 모집하지 않고 적극적으로
    - Wexham Park Hospital
  - South Shields, England, 영국, NE34 0PL
    - 모병
    - South Tyneside District Hospital
    - 연락하다:
      
      Alistair Roy, MD
  - Southampton, England, 영국, SO16 6YD
    - 모병
    - Southampton General Hospital
    - 연락하다:
      
      Ahilanandan Dushianthan, MD
  - Stockport, England, 영국, SK2 7JE
    - 모병
    - Stepping Hill Hospital
    - 연락하다:
      
      Hywel Garrard, MD
  - Stockton-on-Tees, England, 영국, TS19 8PE
    - 모병
    - University Hospital of North Tees
    - 연락하다:
      
      Farooq Brohi, MD
  - Stoke-on-Trent, England, 영국, ST4 6QG
    - 모병
    - Royal Stoke University Hospital
    - 연락하다:
      
      Ramprasad Matsa, MD
  - Sunderland, England, 영국, SR4 7TP
    - 모병
    - Sunderland Royal Hospital
    - 연락하다:
      
      Alistair Roy, MD
  - Sutton in Ashfield, England, 영국, NG17 4JL
    - 모병
    - King's Mill Hospital
    - 연락하다:
      
      Sandaruwan Herath, MD
  - Swindon, England, 영국, SN3 6BB
    - 모병
    - Western General Hospital
    - 연락하다:
      
      Jonathan Rhodes, MD
  - Swindon, England, 영국, SN3 6BB
    - 모집하지 않고 적극적으로
    - Great Western Hospital
  - Taunton, England, 영국, TA1 5DA
    - 모병
    - Musgrove Park Hospital
    - 연락하다:
      
      Richard Innes, MD
  - Torquay, England, 영국, TQ2 7AA
    - 모병
    - Torbay Hospital
    - 연락하다:
      
      Adam Revill, MD
  - Truro, England, 영국, TR1 3LJ
    - 모병
    - Royal Cornwall Hospital
    - 연락하다:
      
      Michael Spivey, MD
  - Uxbridge, England, 영국, UB9 6JH
    - 완전한
    - Harefield Hospital
  - Watford, England, 영국, WD18 0HB
    - 모병
    - Watford General Hospital
    - 연락하다:
      
      Valarie Page, MD
  - Westcliff-on-Sea, England, 영국, ISS0 0RY
    - 모집하지 않고 적극적으로
    - Southend Hospital
  - Whitehaven, England, 영국, CA28 8JG
    - 빼는
    - West Cumberland Hospital
  - Wigan, England, 영국, WN1 2NN
    - 모집하지 않고 적극적으로
    - Royal Albert Edward Infirmary
  - Winchester, England, 영국, SO22 5DG
    - 모병
    - Royal Hampshire County Hospital
    - 연락하다:
      
      Irina Grecu, MD
  - Wolverhampton, England, 영국, WV10 0QP
    - 모집하지 않고 적극적으로
    - New Cross Hospital Wolverhampton
  - Worcester, England, 영국, WR5 1DD
    - 모집하지 않고 적극적으로
    - Worcestershire Royal Hospital
  - York, England, 영국, Y031 8HE
    - 모병
    - York Teaching Hospital
    - 연락하다:
      
      Joseph Carter, MD
- Northern Ireland
  - Antrim, Northern Ireland, 영국, BT41 2RL
    - 모병
    - Antrim Area Hospital
    - 연락하다:
      
      Paul Johnston, MD
  - Belfast, Northern Ireland, 영국, BT14 6AB
    - 모병
    - Mater Hospital
    - 연락하다:
      
      Michael McGinlay, MD
  - Belfast, Northern Ireland, 영국, BT9 7AB
    - 모병
    - Belfast City Hospital
    - 연락하다:
      
      Michael McGinlay, MD
  - Belfast, Northern Ireland, 영국, BT12 6BA
    - 모병
    - Royal Victoria Hospital Belfast
    - 연락하다:
      
      Michael McGinlay, MD
  - Londonderry, Northern Ireland, 영국, BT47 6SB
    - 모병
    - Altnagelvin Hospital
    - 연락하다:
      
      Adrian Donnelly, MD
- Scotland
  - Aberdeen, Scotland, 영국, AB25 2ZN
    - 완전한
    - Aberdeen Royal Infirmary
  - Dundee, Scotland, 영국, DD1 9SY
    - 모병
    - Ninewells Hospital
    - 연락하다:
      
      James Chambers, MD
  - Edinburgh, Scotland, 영국, EH16 4SA
    - 모병
    - Royal Infirmary of Edinburgh
    - 연락하다:
      
      Thomas Craven, MD
  - Glasgow, Scotland, 영국, G4 0SF
    - 모병
    - Glasgow Royal Infirmary
    - 연락하다:
      
      Kathryn Puxty, MD
  - Glasgow, Scotland, 영국, G51 4TF
    - 모병
    - Queen Elizabeth University Hospital, Glasgow
    - 연락하다:
      
      Malcolm Sim, MD
  - Paisley, Scotland, 영국, PA2 9PN
    - 모병
    - Royal Alexandra Hospital
    - 연락하다:
      
      Kevin Rooney, MD
- Wales
  - Abergavenny, Wales, 영국, NP7 7EG
    - 모집하지 않고 적극적으로
    - Neville Hall Hospital
  - Bodelwyddan, Wales, 영국, LL18 5UJ
    - 모집하지 않고 적극적으로
    - Glan Clwyd Hospital
  - Bridgend, Wales, 영국, CF31 1RQ
    - 모집하지 않고 적극적으로
    - Princess of Wales Hospital
  - Cardiff, Wales, 영국, CF14 4XW
    - 모집하지 않고 적극적으로
    - Cardiff and Vale University Hospital Wales
  - Carmarthen, Wales, 영국, SA31 2AF
    - 정지된
    - Glangwilli Hospital
  - Cwmbran, Wales, 영국, NP44 8YN
    - 모집하지 않고 적극적으로
    - Grange University Hospital
  - Newport, Wales, 영국, NP20 2UB
    - 정지된
    - Royal Gwent Hospital
  - Pont-y-clun, Wales, 영국, CF72 8XR
    - 모집하지 않고 적극적으로
    - Royal Glamorgan Hospital
  - Swansea, Wales, 영국, SA6 6NL
    - 모집하지 않고 적극적으로
    - Morriston Hospital
  - Wrexham, Wales, 영국, LL13 7TD
    - 모병
    - Wrexham Maelor Hospital
    - 연락하다:
      
      David Southern, MD
이스라엘
- - Haifa, 이스라엘, 3109601
    - 빼는
    - Rambam Medical Center
  - Petah Tikva, 이스라엘, 4941492
    - 정지된
    - Beilinson Hospital, Rabin Medical Center
  - Poria – Neve Oved, 이스라엘, 1528001
    - 빼는
    - The Baruch Padeh Medical Center
이탈리아
- - Brescia, 이탈리아, 25123
    - 모병
    - AO Spedali Civili di Brescia
    - 연락하다:
      
      Simone Piva, MD
  - Milan, 이탈리아, 20132
    - 모병
    - IRCCS Ospedale San Raffaele
    - 연락하다:
      
      Giovanni Landoni, MD
  - Milan, 이탈리아, 20089
    - 모병
    - Humanitas Research Hospital
    - 연락하다:
      
      Maurizio Cecconi, MD
  - Milan, 이탈리아, 20122
    - 모병
    - Ca' Granda Ospedale Maggiore Policlinico
    - 연락하다:
      
      Francesco Blasi, MD
  - Palermo, 이탈리아, 90127
    - 모병
    - Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
    - 연락하다:
      
      Andrea Cortegiani, MD
  - Palermo, 이탈리아, 90127
    - 모병
    - Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione
    - 연락하다:
      
      Gennaro Martucci, MD
  - Reggio Emilia, 이탈리아, 42123
    - 모병
    - Arcispedale S. Maria Nuova
    - 연락하다:
      
      Elena Mantovani, MD
  - Rimini, 이탈리아, 47923
    - 아직 모집하지 않음
    - Ospedale Infermi di Rimini
    - 연락하다:
      
      Jonathan Montomoli, MD
인도
- Tamil Nadu
  - Chennai, Tamil Nadu, 인도, 600006
    - 모집하지 않고 적극적으로
    - Apollo Main Hospital
  - Chennai, Tamil Nadu, 인도, 600010
    - 모병
    - Apollo First Med Hospital
    - 연락하다:
      
      Meghena Mathew, MD
  - Chennai, Tamil Nadu, 인도, 600095
    - 모집하지 않고 적극적으로
    - Apollo Vanagaram Hospital
  - Chennai, Tamil Nadu, 인도, 600096
    - 모병
    - Apollo Speciality Hospital - OMR
    - 연락하다:
      
      Deva Jayakumar, MD
일본
- Kanagawa
  - Kawasaki, Kanagawa, 일본, 216-8511
    - 모병
    - St Marianna University School of Medicine
  - Yokohama, Kanagawa, 일본, 236-0004
    - 모병
    - Yokohama City University Hospital
  - Yokohama, Kanagawa, 일본, 241-0811
    - 모병
    - St. Marianna University Yokohama City Seibu Hospital
- Kumamoto
  - Minami, Kumamoto, 일본, 861-4193
    - 모병
    - Saiseikai Kumamoto Hospital
- Osaka
  - Osaka, Osaka, 일본, 534-0021
    - 모병
    - Osaka City General Hospital
- Tokyo
  - Tokyo, Tokyo, 일본, 130-8575
    - 모병
    - Nerima Hikarigaoka Hospital
  - Tokyo, Tokyo, 일본, 130-8575
    - 모병
    - Tokyo Metropolitan Bokutoh Hospital
  - Tokyo, Tokyo, 일본, 174-0051
    - 모병
    - Itabashi Chuo Medical Center
  - Tokyo, Tokyo, 일본, 279-0001
    - 모병
    - Tokyo bay Urayasu-Ichikawa Medical Center
- Wakayama
  - Wakayama, Wakayama, 일본, 641-8509
    - 모병
    - Wakayama Medical University
체코
- - Prague, 체코, 10000
    - 모병
    - Fakultní nemocnice Královské Vinohrady
    - 연락하다:
      
      František Duška, MD
  - Teplice, 체코, 41501
    - 정지된
    - Teplice Hospital
캐나다
- Alberta
  - Calgary, Alberta, 캐나다, T2W 1S7
    - 모집하지 않고 적극적으로
    - Foothills Medical Centre
  - Calgary, Alberta, 캐나다, T2W 1S7
    - 모집하지 않고 적극적으로
    - Peter Lougheed Centre
  - Calgary, Alberta, 캐나다, T2W 1S7
    - 모집하지 않고 적극적으로
    - Rockyview General Hospital
  - Calgary, Alberta, 캐나다, T2W 1S7
    - 모집하지 않고 적극적으로
    - South Health Campus
  - Edmonton, Alberta, 캐나다, T5H 3V9
    - 모병
    - Royal Alexandra Hospital, Alberta
    - 연락하다:
      
      Demetrios Kutsogiannis, MD
  - Edmonton, Alberta, 캐나다, T6G 2C8
    - 모병
    - University of Alberta Hospital
    - 연락하다:
      
      Wendy Sligl, MD
- British Columbia
  - Surrey, British Columbia, 캐나다, V3V 1Z2
    - 아직 모집하지 않음
    - Surrey Memorial Hospital
    - 연락하다:
      
      Anish Mitra, MD
- Manitoba
  - Winnipeg, Manitoba, 캐나다, R3A 1R9
    - 모병
    - Health Sciences Centre Winnipeg
    - 연락하다:
      
      Ryan Zarychanski, MD
  - Winnipeg, Manitoba, 캐나다, R2H 2A6
    - 모병
    - St Boniface General Hospital
    - 연락하다:
      
      Ryan Zarychanski, MD
  - Winnipeg, Manitoba, 캐나다, R3J 3M7
    - 모병
    - Grace Hospital
    - 연락하다:
      
      Gloria Vazquez-Grande, MD
- New Brunswick
  - Fredericton, New Brunswick, 캐나다, E3B 4R3
    - 아직 모집하지 않음
    - Dr. Everett Chalmers Regional Hospital
    - 연락하다:
      
      Zeeshan Aslam, MD
  - Fredericton, New Brunswick, 캐나다, E3B 4R3
    - 아직 모집하지 않음
    - The Moncton Hospital
    - 연락하다:
      
      Daniel Smyth, MD
  - Fredericton, New Brunswick, 캐나다, E3B 4R3
    - 아직 모집하지 않음
    - The Saint John General Hospital
    - 연락하다:
      
      Stephen Robinson, MD
- Ontario
  - Brampton, Ontario, 캐나다, L6R 3J7
    - 모병
    - William Osler Health System
    - 연락하다:
      
      Alexandra Binnie, MD
  - Brantford, Ontario, 캐나다, N3R 1G9
    - 모병
    - Brantford General Hospital
    - 연락하다:
      
      Brenda Reeve, MD
  - Hamilton, Ontario, 캐나다, L8N 4A6
    - 모병
    - St. Joseph's Healthcare Hamilton
    - 연락하다:
      
      Deborah Cook, MD
  - Hamilton, Ontario, 캐나다, L8L 8E7
    - 모병
    - Juravinski Hospital
    - 연락하다:
      
      Bram Rochwerg, MD
  - Hamilton, Ontario, 캐나다, L8L 8E7
    - 모병
    - Hamilton general Hospital
    - 연락하다:
      
      Alison Fox-Robichaud, MD
  - Kingston, Ontario, 캐나다, K7L 2V7
    - 모집하지 않고 적극적으로
    - Kingston Health Sciences Centre
  - Kitchener, Ontario, 캐나다, N2G 4K9
    - 모병
    - Grand River Hospital
    - 연락하다:
      
      Theresa Liu, MD
  - Kitchener, Ontario, 캐나다, N2M 1B2
    - 모병
    - St Mary's General Hospital
    - 연락하다:
      
      Rebecca Kruisselbrink, MD
  - Ottawa, Ontario, 캐나다, K1H 8L6
    - 모병
    - The Ottawa Hospital
    - 연락하다:
      
      Lauralyn McIntyre, MD
  - Saint Catharines, Ontario, 캐나다, L2S 0A9
    - 모병
    - Niagara Health
    - 연락하다:
      
      Jennifer Tsang, MD
  - Thunder Bay, Ontario, 캐나다, P7B 6V4
    - 모집하지 않고 적극적으로
    - Thunder Bay General Hospital
  - Toronto, Ontario, 캐나다, M5G 2C4
    - 모병
    - Toronto General Hospital
    - 연락하다:
      
      Lorenzo del Sorbo, MD
  - Toronto, Ontario, 캐나다, M4N 3M5
    - 모병
    - Sunnybrook Health Sciences Centre
    - 연락하다:
      
      Rob Fowler, MD
  - Toronto, Ontario, 캐나다, M5T 2S8
    - 모병
    - Toronto Western Hospital
    - 연락하다:
      
      Elizabeth Wilcox, MD
  - Toronto, Ontario, 캐나다, M5G 1X5
    - 모병
    - Mount Sinai Hospital
    - 연락하다:
      
      Sangeeta Mehta, MD
  - Toronto, Ontario, 캐나다, M5B 1W8
    - 모병
    - St. Michael's Hospital Unity Health Toronto
    - 연락하다:
      
      John Marshall, MD
  - Toronto, Ontario, 캐나다, M6R 1B5
    - 모집하지 않고 적극적으로
    - St Joseph's Health Centre
- Quebec
  - Lévis, Quebec, 캐나다, G6V 3Z1
    - 아직 모집하지 않음
    - CIUSS Chaudieres-Appalaches (Levis)
    - 연락하다:
      
      Patrick Archambault, MD
  - Montreal, Quebec, 캐나다, H3H 2R9
    - 모병
    - McGill University Health Centre
    - 연락하다:
      
      Kosar Khwaja, MD
  - Montreal, Quebec, 캐나다, H2X 0A9
    - 모병
    - Centre Hospitalier de l'Universite de Montreal
    - 연락하다:
      
      Michael Chasse, MD
  - Montreal, Quebec, 캐나다, H1T 2M4
    - 모집하지 않고 적극적으로
    - Hospital Maisonneuve-Rosemont
  - Montreal, Quebec, 캐나다, H2B 1K3
    - 아직 모집하지 않음
    - Hôpital Fleury
    - 연락하다:
      
      Thomas Hemmerling, MD
  - Montreal, Quebec, 캐나다, H4J 1C5
    - 모병
    - Hopital du Sacre-Coeur de Montreal
    - 연락하다:
      
      Martin Albert, MD
  - Québec, Quebec, 캐나다, G1V 4G5
    - 모병
    - IUCPQ-UL
    - 연락하다:
      
      Francois Lellouche, MD
  - Québec, Quebec, 캐나다, G1R 2J6
    - 모병
    - CHU de Québec - Université Laval
    - 연락하다:
      
      Alexis Turgeon, MD
  - Sherbrooke, Quebec, 캐나다, J1J 3H5
    - 모병
    - Centre Hospitalier de l'Université de Sherbrooke
    - 연락하다:
      
      Francois Lamontagne, MD
- Saskatchewan
  - Saskatoon, Saskatchewan, 캐나다, S7K 0M7
    - 모병
    - Regina General Hospital
    - 연락하다:
      
      Eric Sy, MD
콜롬비아
- Cundinamarca
  - Chía, Cundinamarca, 콜롬비아
    - 모병
    - Universidad de La Sabana
크로아티아
- - Požega, 크로아티아, 34000
    - 모병
    - General County Hospital Požega
    - 연락하다:
      
      Zdravko Andrić, MD
  - Zagreb, 크로아티아, 10000
    - 모병
    - University Hospital Centre Zagreb
    - 연락하다:
      
      Ana Vujaklija Brajković, MD
  - Zagreb, 크로아티아, 10000
    - 빼는
    - University Hospital for Infectious Diseases
파키스탄
- Sindh
  - Karachi, Sindh, 파키스탄, 75000
    - 모병
    - Ziauddin University Hospital Clifton Campus
    - 연락하다:
      
      Madiha Hashmi, MD
  - Karachi, Sindh, 파키스탄, 75300
    - 모병
    - Abbasi Shaheed Hospital
    - 연락하다:
      
      Aneela Kidwai, MD
  - Karachi, Sindh, 파키스탄, 75510
    - 모병
    - National Institute of Cardiovascular Diseases, Karachi
    - 연락하다:
      
      Nawal Salahuddin, MD
  - Karachi, Sindh, 파키스탄, 75600
    - 모병
    - South City Hospital, Karachi
    - 연락하다:
      
      Nasir Khoso, MD
  - Karachi, Sindh, 파키스탄
    - 모병
    - Ziauddin University North Nazimabad Campus
    - 연락하다:
      
      Quratul Ain, MD
포르투갈
- - Abrantes, 포르투갈
    - 모병
    - Centro Hospitalar do Medio Tejo
    - 연락하다:
      
      Nuno Catorze, M.D.
  - Lisbon, 포르투갈, 1169-050
    - 정지된
    - Hospital Ocidental
  - Lisbon, 포르투갈
    - 정지된
    - Hospital Lusíadas Lisbon
프랑스
- - Argenteuil, 프랑스, 95107
    - 모집하지 않고 적극적으로
    - CH Argenteuil
  - Aurillac, 프랑스, 15000
    - 완전한
    - Centre Hospitalier Henri Mondor d'Aurillac
  - Beauvais, 프랑스, 60000
    - 모집하지 않고 적극적으로
    - Beauvais General Hospital
  - Belfort, 프랑스, 90400
    - 정지된
    - Hopital Nord Franche-Comte
  - Boulogne-Billancourt, 프랑스, 92100
    - 모병
    - Ambroise Pare Hospital
    - 연락하다:
      
      Antoine Vieillard Baron, MD
  - Béthune, 프랑스, 62660
    - 모병
    - Centre hospitalier Bethune Beuvry
    - 연락하다:
      
      Christophe Vinsonneau, MD
  - Dax, 프랑스, 40100
    - 모병
    - CH de Dax
    - 연락하다:
      
      Adrien Auvet, MD
  - Dieppe, 프랑스, 76202
    - 모병
    - Centre Hospitalier de Dieppe
    - 연락하다:
      
      Peierre-Louis Declercq, MD
  - Dijon, 프랑스, 21000
    - 모병
    - CHU Dijon Bourgogne
    - 연락하다:
      
      Jean-Pierre Quenot, MD
  - Eaubonne, 프랑스, 95600
    - 모집하지 않고 적극적으로
    - Hopital Simone Veil Eaubonne
  - Garches, 프랑스, 92380
    - 모병
    - Hospital Raymond Poincare
    - 연락하다:
      
      Djillali Annane, MD
  - La Roche-sur-Yon, 프랑스, 85000
    - 모병
    - CHD Vendee
    - 연락하다:
      
      Gwenael Colin, MD
  - Le Mans, 프랑스, 72027
    - 모병
    - Centre Hospitalier Le Mans
    - 연락하다:
      
      Christophe Guitton, MD
  - Limoges, 프랑스, 87000
    - 모병
    - CHU Dupuytren
    - 연락하다:
      
      Francois Bruno, MD
  - Melun, 프랑스, 77000
    - 모집하지 않고 적극적으로
    - Centre Hospitalier de Melun
  - Mont-de-Marsan, 프랑스, 40024
    - 모병
    - Centre Hospitalier Layne - Mont-de-Marsan
    - 연락하다:
      
      Arnaud Sement, MD
  - Morlaix, 프랑스, 29600
    - 모병
    - Centre Hospitalier des Pays de Morlaix
    - 연락하다:
      
      Pierre Yves Egreteau, MD
  - Orléans, 프랑스, 45100
    - 모집하지 않고 적극적으로
    - CHR d'Orleans
  - Paris, 프랑스, 75010
    - 모집하지 않고 적극적으로
    - Lariboisiere Hospital
  - Paris, 프랑스, 75020
    - 모집하지 않고 적극적으로
    - Hopital Tenon
  - Strasbourg, 프랑스, 67200
    - 모집하지 않고 적극적으로
    - Hopital de Hautepierre Strasbourg
  - Strasbourg, 프랑스, 67000
    - 모병
    - Nouvel Hopital Civil Strasbourg
    - 연락하다:
      
      Ferhat Meziani, MD
  - Tours, 프랑스, 37000
    - 모병
    - CHRU Tours Hopital Bretonneau
    - 연락하다:
      
      Emmanuelle Mercier, MD
  - Étampes, 프랑스, 91150
    - 모집하지 않고 적극적으로
    - Sud Essonne Hospital Etampes
핀란드
- - Helsinki, 핀란드, 00290
    - 정지된
    - Helsinki University Hospital
  - Tampere, 핀란드, 33520
    - 정지된
    - Tampere University Hospital
헝가리
- - Nyíregyháza, 헝가리, 4400
    - 완전한
    - Jósa András County Hospital
  - Ózd, 헝가리, 3600
    - 완전한
    - Almási Balogh Pál Kórház
호주
- Australian Capital Territory
  - Canberra, Australian Capital Territory, 호주, 2605
    - 모병
    - Canberra Hospital
- New South Wales
  - Bankstown, New South Wales, 호주, 2200
    - 모병
    - Bankstown-Lidcombe Hospital
  - Blacktown, New South Wales, 호주, 2148
    - 모병
    - Blacktown Hospital
  - Campbelltown, New South Wales, 호주, 2560
    - 모병
    - Campbelltown Hospital
  - Caringbah, New South Wales, 호주, 2229
    - 모병
    - Sutherland Hospital
  - Concord, New South Wales, 호주, 2139
    - 모병
    - Concord Hospital
  - Dubbo, New South Wales, 호주, 2830
    - 모병
    - Dubbo Base Hospital
  - Frenchs Forest, New South Wales, 호주, 2086
    - 모병
    - Northern Beaches Hospital
  - Kingswood, New South Wales, 호주, 2750
    - 모병
    - Nepean Hospital
  - Kogarah, New South Wales, 호주, 2217
    - 모병
    - St. George Hospital
  - Liverpool, New South Wales, 호주, 2170
    - 모병
    - Liverpool Hospital
  - Newcastle, New South Wales, 호주, 2305
    - 모병
    - John Hunter Hospital
  - Orange, New South Wales, 호주, 2800
    - 아직 모집하지 않음
    - Orange Health Service
  - Sydney, New South Wales, 호주, 2065
    - 모병
    - Royal North Shore Hospital
  - Sydney, New South Wales, 호주, 2010
    - 모병
    - St Vincent's Hospital Sydney
  - Sydney, New South Wales, 호주, 2031
    - 모병
    - Prince of Wales Hospital
  - Sydney, New South Wales, 호주, 2050
    - 아직 모집하지 않음
    - Royal Prince Alfred Hospital
  - Sydney, New South Wales, 호주, 2500
    - 모병
    - Wollongong Hospital
  - Wagga Wagga, New South Wales, 호주, 2650
    - 아직 모집하지 않음
    - Wagga Wagga Base Hospital
  - Westmead, New South Wales, 호주, 2145
    - 모병
    - Westmead Hospital
- Northern Territory
  - Darwin, Northern Territory, 호주, 0810
    - 아직 모집하지 않음
    - Royal Darwin Hospital,
- Queensland
  - Birtinya, Queensland, 호주, 4575
    - 아직 모집하지 않음
    - Sunshine Coast University Hospital
  - Brisbane, Queensland, 호주, 4102
    - 모병
    - Princess Alexandra Hospital
  - Brisbane, Queensland, 호주, 4032
    - 모병
    - The Prince Charles Hospital
  - Brisbane, Queensland, 호주, 4101
    - 모병
    - Mater Hospital Brisbane
  - Caboolture, Queensland, 호주, 4510
    - 모병
    - Caboolture Hospital
  - Coopers Plains, Queensland, 호주, 4110
    - 모병
    - Queen Elizabeth II Jubilee Hospital
  - Logan City, Queensland, 호주, 4129
    - 아직 모집하지 않음
    - Logan Hospital
  - Redcliffe, Queensland, 호주, 4020
    - 아직 모집하지 않음
    - Redcliffe Hospital
  - Rockhampton, Queensland, 호주, 4700
    - 아직 모집하지 않음
    - Rockhampton Hospital
  - Southport, Queensland, 호주, 4215
    - 모병
    - Gold Coast University Hospital
  - Toowoomba, Queensland, 호주, 4350
    - 모병
    - Toowoomba Hospital
  - Townsville, Queensland, 호주, 4814
    - 모병
    - Townsville Hospital
- South Australia
  - Adelaide, South Australia, 호주, 5000
    - 모병
    - Royal Adelaide Hospital
  - Adelaide, South Australia, 호주, 5011
    - 모병
    - The Queen Elizabeth Hospital
  - Adelaide, South Australia, 호주, 5112
    - 모병
    - Lyell McEwin Hospital
  - Bedford Park, South Australia, 호주, 5042
    - 모병
    - Flinders Medical Centre
- Tasmania
  - Launceston, Tasmania, 호주, 7250
    - 모병
    - Launceston Hospital
- Victoria
  - Ballarat, Victoria, 호주, 3350
    - 모병
    - Ballarat Base Hospital
  - Bendigo, Victoria, 호주, 3550
    - 모병
    - Bendigo Hospital
  - Berwick, Victoria, 호주, 3806
    - 모병
    - Casey Hospital
  - Box Hill, Victoria, 호주, 3128
    - 모병
    - Box Hill Hospital
  - Clayton, Victoria, 호주, 3168
    - 모병
    - Monash Medical Centre
  - Dandenong, Victoria, 호주, 3175
    - 모병
    - Dandenong Hospital
  - Ferntree Gully, Victoria, 호주, 3156
    - 아직 모집하지 않음
    - Angliss Hospital
  - Footscray, Victoria, 호주, 3011
    - 모병
    - Footscray Hospital
  - Geelong, Victoria, 호주, 3220
    - 모병
    - University Hosptial Geelong
  - Melbourne, Victoria, 호주, 3004
    - 모병
    - The Alfred Hospital
  - Melbourne, Victoria, 호주, 3050
    - 모병
    - Royal Melbourne Hospital
  - Melbourne, Victoria, 호주, 3065
    - 모병
    - St Vincent's Hospital Melbourne
  - Ringwood East, Victoria, 호주, 3135
    - 모병
    - Maroondah Hospital
  - Sunshine, Victoria, 호주, 3021
    - 모병
    - Sunshine Hospital
  - Werribee, Victoria, 호주, 3030
    - 모병
    - Werribee Mercy Hospital
- Western Australia
  - Midland, Western Australia, 호주, 6056
    - 모병
    - St John of God Hospital Midland
  - Murdoch, Western Australia, 호주, 6150
    - 아직 모집하지 않음
    - St John of God Hospital Murdoch
  - Perth, Western Australia, 호주, 6000
    - 모병
    - Royal Perth Hospital
  - Perth, Western Australia, 호주, 6150
    - 모병
    - Fiona Stanley Hospital
  - Perth, Western Australia, 호주, 6009
    - 모병
    - Sir Charles Gairdner Hospital
  - Subiaco, Western Australia, 호주, 6008
    - 모병
    - St John of God Subiaco

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

4주 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

The eligibility criteria for the Platform are applied at multiple levels. One level is that there are inclusion and exclusion criteria that determine eligibility for randomization within the Platform. Another level is that, once eligible for inclusion within the Platform, additional criteria (typically exclusion criteria) are applied that are specific to each domain. Finally, intervention-level eligibility criteria may be applied for interventions within a domain. A patient is eligible for inclusion within a domain when:

All Platform inclusion criteria are met
None of the Platform exclusion criteria are met
Domain-specific eligibility criteria are met
The patient is eligible for at least two interventions within a domain

As such, the key "inclusion criteria" for being eligible for a domain are that the patient is eligible for the Platform.

PLATFORM INCLUSION CRITERIA:

Hospitalised patient
Acute respiratory tract infection
Aged 28 days or older

PLATFORM EXCLUSION CRITERIA:

Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
Patient is expected to be discharged from hospital within the next 24 hours
Previous participation in this REMAP within the last 90 days

DOMAIN-SPECIFIC ELIGIBILITY CRITERIA:

Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

주 목적: 치료
할당: 무작위
중재 모델: 요인 할당
마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔 참가자 그룹 / 팔 시험 프로토콜에 따라 특정 중재/치료를 받거나 중재를 받지 않는 임상 시험 참가자 그룹 또는 하위 그룹입니다.	개입 / 치료 개입 / 치료 임상 연구의 초점이 되는 프로세스 또는 작업입니다. 개입에는 약물, 의료 기기, 절차, 백신 및 조사 중이거나 이미 사용 가능한 기타 제품이 포함됩니다. 개입에는 교육이나 식이요법 및 운동 수정과 같은 비침습적 접근법도 포함될 수 있습니다.
다른: Antibiotic Domain Patients with community-acquired pneumonia and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions. Note: the ceftaroline + macrolide intervention has been closed to recruitment.	의약품: Ceftriaxone + Macrolide The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. 의약품: Moxifloxacin or Levofloxacin The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. 의약품: Piperacillin-tazobactam + Macrolide The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. 의약품: Ceftaroline + Macrolide The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. Note: this intervention is now closed. 의약품: Amoxicillin-clavulanate + Macrolide The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
다른: Macrolide Duration Domain Patients with community-acquired pneumonia who have been allocated to receive a beta-lactam + macrolide intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy	의약품: Standard course macrolide Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5. The dosing of and route of administration is not protocolised, the following guidance is provided: Initial IV administration of a macrolide is strongly preferred The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted. The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted. 의약품: Extended course macrolide Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first). The dosing of and route of administration is not protocolised, the following guidance is provided: Initial IV administration of a macrolide is strongly preferred The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted. The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
다른: Corticosteroid Domain Patients with severe lower-respiratory tract infection will be randomised to a steroid use strategy. Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19. Note: the fixed-course hydrocortisone has been closed to recruitment	다른: No systemic corticosteroid Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first). 의약품: Fixed-duration Hydrocortisone 50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Note: this intervention is now closed. 의약품: Shock-dependent hydrocortisone 50mg IV hydrocortisone every 6 hours while the patient is in septic shock 의약품: Fixed-duration higher dose Hydrocortisone 100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed. 의약품: Fixed-duration dexamethasone 6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
다른: Influenza Antiviral Domain Patients with microbiological testing confirmed influenza infection will be randomised to one of six interventions.	다른: No antiviral agent for influenza No antiviral agent intended to be active against influenza infection is to be administered 의약품: Five-days oseltamivir Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first) 의약품: Ten-days oseltamivir Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first) 의약품: Baloxavir Marboxil Baloxavir marboxil administered on days 1 and 4 post-randomisation. 의약품: Five-days oseltamivir + baloxavir marboxil Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation. 의약품: Ten-days oseltamivir + baloxavir marboxil Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
다른: COVID-19 Antiviral Domain Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin. Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control. This domain is now closed.	다른: No antiviral agent for COVID-19 No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered 의약품: Lopinavir / Ritonavir Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Note: this intervention is now closed. 의약품: Hydroxychloroquine Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed. 의약품: Hydroxychloroquine + lopinavir/ritonavir Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed. 의약품: Ivermectin Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day. Note: this intervention is now closed.
다른: COVID-19 Immune Modulation Domain Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions. Note: this domain is now closed.	다른: No immune modulation for COVID-19 No immune modulating agent intended to be active against COVID-19 is to be administered. Note: this intervention is now closed. 의약품: Interferon beta-1a IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first. Note: this intervention is now closed. 다른 이름들: IFN-β1a 의약품: Anakinra A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours. In patients with renal impairment, anakinra will be administered on alternate days. Note: this intervention is now closed. 의약품: Tocilizumab Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period. Note: this intervention is now closed. 의약품: Sarilumab Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period. Note: this intervention is now closed. 의약품: Tocilizumab Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.
다른: Anticoagulation Domain Patients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy. Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. This domain is now closed.	의약품: Local standard venous thromboprophylaxis Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Note: this intervention is now closed. 의약품: Therapeutic dose anticoagulation Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician. Note: this intervention is now closed. 의약품: Conventional low dose thromboprophylaxis Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain. 의약품: Intermediate dose thromboprophylaxis Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain. 의약품: Continuation of therapeutic dose anticoagulation Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
다른: Immunoglobulin Domain Immunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma. Note: an earlier version of this domain was not restricted to immunosuppressed patients.	다른: No immunoglobulin No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered. 생물학적: Convalescent plasma Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation. 생물학적: Delayed administration of convalescent plasma Note: this intervention is now closed.
다른: Vitamin C Domain Patients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C. Note: this domain is now closed.	다른: No vitamin C No high dose intravenous vitamin C is to be administered Note: this intervention is now closed. 의약품: Vitamin C Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses Note: this intervention is now closed.
다른: Simvastatin Domain Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin. Note: this domain is now closed.	다른: No simvastatin No simvastatin intended to be active against COVID-19 is to be administered Note: this intervention is now closed. 의약품: Simvastatin Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation Note: this intervention is now closed.
다른: Antiplatelet Domain Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor. Note: this domain is now closed.	다른: No antiplatelet No antiplatelet agent or NSAID to be administered. Note: this intervention is now closed. 의약품: Aspirin Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed. 다른 이름들: 아세틸 살리실산 의약품: P2Y12 inhibitor Site-selected P2Y12 inhibitor: Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first. Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day. Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed. 다른 이름들: 프라수그렐 클로피도그렐 티카그렐러
다른: Mechanical Ventilation Domain Patients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy	절차: Clinician-preferred mechanical ventilation strategy Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters 절차: Protocolised mechanical ventilation strategy Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
다른: COVID-19 Immune Modulation (2) Domain Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions. Note: this domain is now closed.	다른: No immune modulation for COVID-19 No immune modulating agent intended to be active against COVID-19 is to be administered. Note: this intervention is now closed. 의약품: Eritoran Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital Note: this intervention is now closed. 의약품: Apremilast Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
다른: ACE2 RAS Domain Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies. Note: this domain is now closed.	다른: No renin-angiotensin system inhibitor No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10. Note: this intervention is now closed. 의약품: Angiotensin converting enzyme inhibitor Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed. 다른 이름들: 리시노프릴 페린도프릴 라미프릴 캅토프릴 에날라프릴 트란돌라프릴 의약품: Angiotensin Receptor Blockers Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed. 다른 이름들: 발사르탄 로사르탄 칸데사르탄 이르베사르탄 올메사르탄 텔미사르탄 의약품: ARB + DMX-200 Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first. ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily. Note: this intervention is now closed.
다른: Cysteamine Domain Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine. Note: this domain is now closed.	다른: No cysteamine No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first. Note: this intervention is now closed. 의약품: Cysteamine Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first. Note: this intervention is now closed.
다른: Endothelial Domain Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib.	다른: No endothelial modulator No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered. 의약품: Imatinib Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
다른: Influenza Immune Modulation Patients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of three interventions.	의약품: Tocilizumab Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period. Note: this intervention is now closed. 의약품: Tocilizumab Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period. 다른: No Immune Modulator for Influenza No immune modulating agent intended to be active against influenza is to be administered. 의약품: Baricitinib Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
다른: COVID-19 Antiviral (II) Domain Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to one of up to four interventions.	다른: No antiviral agent for COVID-19 No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered 의약품: Nirmatrelvir/ritonavir Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. 다른 이름들: 팍슬로비드 의약품: Remdesivir Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first. 의약품: Nirmatrelvir/ritonavir + remdesivir Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
다른: Tropical Antibiotic Domain Patients with community-acquired pneumonia in regions at locations where or when empiric cover for melioidosis is appropriate, and requiring empiric antibiotic therapy including cover for melioidosis, will be randomised one of two antibiotic interventions	의약품: Amoxicillin-clavulanate + Ceftazidime + Macrolide The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. 의약품: Meropenem + Macrolide The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정	측정값 설명	기간
Survival and Recovery Trajectory up to day 90 기간: Day 90	The primary endpoint, named Survival and Recovery Trajectory, is a composite of: 90-day all-cause mortality and, among survivors, the number of days on which the patient was not receiving organ failure support during the index hospitalisation, up to the end of study day 28; and, among survivors who never receive organ failure support, hospital free days for the index hospitalisation up to the end of study day 28. For the purposes of this endpoint, organ failure support is defined as: Extracorporeal life support Invasive mechanical ventilation Non-invasive ventilation High-flow nasal oxygen Continuous infusion of vasopressors, inotropes or both	Day 90

2차 결과 측정

결과 측정	측정값 설명	기간
All-cause mortality 기간: Day 90	All-cause mortality to day 90 post-randomisation	Day 90
Days alive and free from organ-failure support 기간: Day 28	Days alive and free from organ failure support during the index hospitalisation to day 28	Day 28
Days alive and out of hospital 기간: Day 28	Days alive and out of hospital for the index hospitalisation, to day 28	Day 28
Health-related Quality of life assessment 기간: 6 months	EQ5D-5L and WHODAS 2.0 (not completed in all regions)	6 months

기타 결과 측정

결과 측정	측정값 설명	기간
Domain-Specific Secondary Outcome 기간: During the index hospitalisation to Day 90 post-randomisation, unless otherwise specified	Each domain may specify domain-specific secondary outcomes. Please see relevant Domain-Specific Protocol Documents for details.	During the index hospitalisation to Day 90 post-randomisation, unless otherwise specified

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

UMC Utrecht

협력자

National University Hospital, Singapore

Berry Consultants

University of Pittsburgh Medical Center

Global Coalition for Adaptive Research

Australian and New Zealand Intensive Care Research Centre

Intensive Care National Audit & Research Centre

Nat Intensive Care Surveillance - MORU

Medical Research Institute of New Zealand

St. Marianna University School of Medicine

Unity Health

Universidad de La Sabana, Colombia

수사관

연구 의자: Steve Webb, Prof, Monash University, Study Chair REMAP-CAP Australia
연구 의자: Colin McArthur, Dr, Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand
연구 의자: Marc Bonten, Prof, UMC Utrecht, Study Chair REMAP-CAP Europe
연구 의자: Lennie Derde, MD, UMC Utrecht, Coordinating Investigator REMAP-CAP Europe
연구 의자: John Marshall, Prof, Unity Health Toronto, Study Chair REMAP-CAP Canada
연구 의자: Derek Angus, Prof, University of Pittsburgh Medical Center, Study Chair REMAP-CAP USA
연구 의자: Luis Felipe Reyes, MD, MSc, PhD, Clínica Universidad de la Sabana, Study Chair REMAP-CAP Colombia

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2016년 4월 11일

기본 완료 (추정된)

2028년 6월 1일

연구 완료 (추정된)

2029년 2월 1일

연구 등록 날짜

최초 제출

2015년 12월 11일

QC 기준을 충족하는 최초 제출

2016년 4월 6일

처음 게시됨 (추정된)

2016년 4월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 30일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

U1111-1189-1653
2015-002340-14 (EudraCT 번호)
602525 (기타 보조금/기금 번호: European Union, FP7-HEALTH-2013-INNOVATION-1, PREPARE)
16/631 (기타 보조금/기금 번호: Health Research Council of New Zealand)
APP1101719 (기타 보조금/기금 번호: National Health and Medical Research Council, Australia)
158584 (기타 보조금/기금 번호: Canadian Institute of Health Research)
2023-507889-89-00 (씨티스)
2023 (미국 NIH 보조금/계약)
2015 (미국 NIH 보조금/계약)
965313 (기타 보조금/기금 번호: European Union, Horizon 2020 research and innovation programme, ECRAID-Base)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

지역사회 획득 폐렴에 대한 무작위, 임베디드, 다단계 적응형 플랫폼 시험 (REMAP-CAP)

연구 개요

상태

정황

개입 / 치료

상세 설명

연구 유형

등록 (추정된)

단계

연락처 및 위치

연구 연락처

연구 연락처 백업

연구 장소

참여기준

자격 기준

공부할 수 있는 나이

건강한 자원 봉사자를 받아들입니다

연구 대상 성별

설명

공부 계획

연구는 어떻게 설계됩니까?

디자인 세부사항

팔의 수

무기와 개입

참가자 그룹 / 팔

개입 / 치료

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정

측정값 설명

기간

2차 결과 측정

결과 측정

측정값 설명

기간

기타 결과 측정

결과 측정

측정값 설명

기간

공동 작업자 및 조사자

스폰서

협력자

수사관

간행물 및 유용한 링크

일반 간행물

유용한 링크

연구 기록 날짜

연구 주요 날짜

연구 시작 (실제)

기본 완료 (추정된)

연구 완료 (추정된)

연구 등록 날짜

최초 제출

QC 기준을 충족하는 최초 제출

처음 게시됨 (추정된)

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

QC 기준을 충족하는 마지막 업데이트 제출

마지막으로 확인됨

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

미국 FDA 규제 기기 제품 연구

미국에서 제조되어 미국에서 수출되는 제품